Drugs / laduviglusib
last change Dec 2018 re-read 2 minutes ago

laduviglusib

Small molecule

Developed for
sensorineural hearing loss disorder
Investigated by
Frequency Therapeutics

Trials 1 · a red edge is where a trial was stopped

20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT03616223 Jul → Dec 2018 sensorineural hearing loss disorder Frequency Therapeutics Completed No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as laduviglusib “Intratympanic injection of FX-322 consists of laduviglusib and sodium valproate” NCT03616223
Known as CHIR 99021 ChEMBL registry synonym — accepted as the source's own label CHEMBL412142
Known as CHIR-911 ChEMBL registry synonym — accepted as the source's own label CHEMBL412142
Known as CHR-00921 ChEMBL registry synonym — accepted as the source's own label CHEMBL412142
Known as CT 99021 ChEMBL registry synonym — accepted as the source's own label CHEMBL412142
Known as FX03 ChEMBL registry synonym — accepted as the source's own label CHEMBL412142
Known as GSK-3 INHIBITOR XVI ChEMBL registry synonym — accepted as the source's own label CHEMBL412142
Known as KIN001-157 ChEMBL registry synonym — accepted as the source's own label CHEMBL412142
Known as LADUVIGLUSIB (CHIR-99021) ChEMBL registry synonym — accepted as the source's own label CHEMBL412142
Modality Small molecule CHEMBL412142